Medicare Watchdog Urges Crackdown on Nursing Home Antipsychotic Use & Fraudulent Diagnoses
Federal Reports Detail Antipsychotic Misuse in Nursing Homes
Concerns are mounting over the inappropriate employ of antipsychotic drugs in nursing homes, with a pair of modern reports from the Department of Health and Human Services Office of Inspector General (HHS OIG) highlighting practices that prioritize staff convenience over resident well-being. The reports, released Thursday, detail how these facilities are utilizing antipsychotics as chemical restraints and artificially inflating quality ratings through inaccurate schizophrenia diagnoses, particularly among residents with dementia. This isn’t a newly identified problem. it’s been the subject of prior research, including a 2020 Congressional investigation and previous reports from the HHS OIG itself. However, the latest findings aim to provide a more detailed understanding of the experiences of residents and caregivers, and to push the Centers for Medicare and Medicaid Services (CMS) toward stronger regulation.
Chemical Restraints and Resident Care
One of the issue briefs from the HHS OIG paints a concerning picture of antipsychotic drugs being used not for their intended purpose – to treat psychosis – but as a means to manage residents’ behaviors and make staff jobs easier. This practice, known as chemical restraint, involves using medication to control a person without addressing the underlying cause of their behavior. The report suggests that facilities are not always following required steps to protect patients when prescribing these powerful drugs. Antipsychotics carry significant risks, including increased risk of stroke, falls, and even death, particularly for older adults with dementia.
Inflated Quality Ratings and Misdiagnosis
The second report from the HHS OIG focuses on a troubling trend: nursing homes inappropriately diagnosing residents with schizophrenia to justify the use of antipsychotic medications. Quality ratings for nursing homes often consider the percentage of residents receiving antipsychotics. By assigning a schizophrenia diagnosis, facilities can mask the use of these drugs and present a more favorable picture of their care. This practice misrepresents the true quality of care and can mislead families and regulators.
A Long-Standing Problem
These issues are not new. Research published in PMC and PMC has long documented the overuse of antipsychotics in nursing homes and the associated harms. A 2020 investigation by the House Ways and Means Democrats further illuminated these concerns. The HHS OIG has also previously highlighted the issue. The authors of the current reports emphasize that their goal isn’t to reveal new information, but to provide more detailed insights into the experiences of those affected and to pressure CMS to grab more decisive action.
Understanding Antipsychotics and Their Risks
Antipsychotic medications work by affecting brain chemicals that influence mood, thought, and behavior. Whereas they can be effective in treating conditions like schizophrenia and bipolar disorder, they also have significant side effects, especially in older adults. These side effects can include drowsiness, dizziness, confusion, movement disorders, and an increased risk of cardiovascular events and stroke. For individuals with dementia, antipsychotics can worsen cognitive decline and increase mortality risk. It’s crucial to remember that these medications should only be used when medically necessary and with careful monitoring.
What Does This Mean for Residents and Families?
The reports raise serious questions about the quality of care in many nursing homes. Families should be vigilant in monitoring their loved ones’ medications and asking questions about any prescribed antipsychotics. It’s important to understand why a medication is being prescribed, what the potential benefits and risks are, and whether there are alternative approaches to managing behavioral symptoms. Residents themselves should be involved in decisions about their care whenever possible. Advocacy groups can also provide support and resources for families navigating the complexities of nursing home care.
The Role of CMS and Future Oversight
The HHS OIG reports are directed at the Centers for Medicare and Medicaid Services (CMS), urging the agency to strengthen its oversight of nursing home medication practices. This could include increasing scrutiny of facilities with high antipsychotic prescribing rates, implementing stricter guidelines for diagnosing schizophrenia in residents with dementia, and providing more training for nursing home staff on appropriate medication management. CMS has not yet publicly responded to the reports, but the findings are likely to fuel ongoing debates about nursing home regulation and quality of care.
What Comes Next: Strengthening Regulation and Improving Care
The immediate next step involves CMS reviewing the OIG’s findings and determining what regulatory changes are needed. This process will likely involve a period of public comment and stakeholder engagement. The agency may also consider increasing funding for enforcement activities and providing technical assistance to nursing homes to facilitate them improve their medication practices. Longer term, continued research is needed to better understand the causes of behavioral symptoms in nursing home residents and to develop non-pharmacological approaches to managing these symptoms. Tara Bannow, who covers hospitals, providers, and insurers for STAT News, can be reached on Signal at tarabannow.70 for further information.